Pacira, Heron Therapeutics initiated at Stifel

Pacira initiated with a Sell at Stifel. Stifel analyst Derek Archila initiated Pacira (PCRX) with a Sell rating and a price target of $41, saying the stock price is not “particularly cheap” following the rally driven by an upward revision to Exparel sales guidance during its Q2 earnings call. The analyst adds that the approval of Heron’s (HRTX) HTX-011 also creates a “medium- to long-term headwind” for Pacira.
https://thefly.com/landingPageNews.php?id=2790371